➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Dow
Mallinckrodt
Harvard Business School
McKinsey

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR JAKAFI

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Jakafi

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01251965 ↗ Phase l/II Study of Ruxolitinib for Acute Leukemia Completed Incyte Corporation Phase 1/Phase 2 2010-12-01 The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01251965 ↗ Phase l/II Study of Ruxolitinib for Acute Leukemia Completed M.D. Anderson Cancer Center Phase 1/Phase 2 2010-12-01 The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease. The safety of the drug will also be studied.
NCT01732445 ↗ Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis Active, not recruiting National Cancer Institute (NCI) Phase 2 2013-04-01 This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
NCT01732445 ↗ Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis Active, not recruiting Mayo Clinic Phase 2 2013-04-01 This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis.
NCT01751425 ↗ Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Recruiting Incyte Corporation Phase 1/Phase 2 2013-07-01 This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.
NCT01751425 ↗ Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Recruiting M.D. Anderson Cancer Center Phase 1/Phase 2 2013-07-01 This is a 2 part study. The goal of the first part of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given with a TKI that you are already taking (such as gleevec, sprycel, or nilotinib) as part of your standard of care treatment. The goal of the second part of this study is to learn if this drug combination can help to control CML. Although you have a good response to therapy, the disease is still detectable at low levels (this is called "minimal residual disease"). Researchers believe that eliminating all detectable evidence of disease may decrease the chances that the leukemia will ever come back. The safety of the drug combination will also be studied in both parts. Ruxolitinib is designed to block a protein called Jak2 that may help keep some leukemia cells alive even with TKI therapy. Blocking this protein may cause the cells to die.
NCT01758588 ↗ Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis Active, not recruiting Merck Sharp & Dohme Corp. Phase 2 2013-01-01 The purpose of this study is to look at the effectiveness of giving patients who have been newly diagnosed with untreated early stage primary myelofibrosis (PMF) a study drug called PEGINTRON (also known as pegylated interferon alfa 2b). This intervention will be compared to the widely employed "watch and wait" (best supportive care) approach for early stage PMF, in which patients are followed closely and treatment initiated only if the disease progresses.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Jakafi

Condition Name

Condition Name for Jakafi
Intervention Trials
Myelofibrosis 13
Primary Myelofibrosis 8
Leukemia 8
Secondary Myelofibrosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Jakafi
Intervention Trials
Primary Myelofibrosis 20
Leukemia 15
Thrombocytosis 9
Thrombocythemia, Essential 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Jakafi

Trials by Country

Trials by Country for Jakafi
Location Trials
United States 143
China 3
Canada 3
Spain 1
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Jakafi
Location Trials
Texas 18
California 9
New York 9
Arizona 8
Missouri 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Jakafi

Clinical Trial Phase

Clinical Trial Phase for Jakafi
Clinical Trial Phase Trials
Phase 3 7
Phase 2/Phase 3 1
Phase 2 28
[disabled in preview] 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Jakafi
Clinical Trial Phase Trials
Not yet recruiting 29
Recruiting 27
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Jakafi

Sponsor Name

Sponsor Name for Jakafi
Sponsor Trials
Incyte Corporation 30
National Cancer Institute (NCI) 13
M.D. Anderson Cancer Center 11
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Jakafi
Sponsor Trials
Other 52
Industry 47
NIH 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKinsey
Colorcon
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.